medigraphic.com
Revista Médica Sinergia

2022, Number 04

<< Back Next >>

Revista Médica Sinergia 2022; 7 (04)

Peyronie’s disease

Angulo MLC, Garita MEA, Salas MJP

Language: Spanish
References: 19
Page:
PDF size: 220.78 Kb.


ABSTRACT

Peyronie's disease, also known as penile fibromatosis, is an acquired connective tissue disorder associated with the appearance of fibrotic nodules in the tunica albuginea of the penis, reducing its local elasticity and curving the penis during erection. Peyronie's disease increases in frequency with age, with its highest incidence during the fifth decade of life. Pathophysiologically, the exact cause of the formation of fibrotic plaques in the tunica albuginea is unknown, mainly associated with micro traumas during penetration. Additionally different hypotheses have been formulated as, for example, the dysfunction of matrix metalloproteinases, by which there would be a persistence of fibrotic tissue. Clinically, there are two spectra of the disease, the acute phase and the stable phase, a patient with an acute picture will present with penile pain, changes in the penis during erection as curvatures or malformations; in a stable picture, the patient has no penile pain during erection and presents a penile curvature without further progression of the malformation. Both presentations are associated with psycho-social affectation of the patients, which is of extreme relevance and must be approached in an integral way with the treatment of the symptoms of the disease. During the clinical evaluation, therapeutic decisions will be made in relation to the extent of penile curvature and oralmedical treatment with pentoxifylline or intralesional injections could be given. Additionally, there is the option of surgical treatment for certain cases of the disease.


REFERENCES

  1. Ziegelmann MJ, Bajic P, Levine LA. Peyronie’s disease: Contemporary evaluation and management. Int J Urol. 2020 Jun;27(6):504–16.

  2. Brant WO, Bella AJ, Lue TF. [Internet]. O'Leary MP, Givens J, editors. Peyronie's disease: Diagnosis and medical management. UpToDate; 2018 [cited 2020Jul26]. Recovered from: https://www.uptodate.com/contents/peyronies-disease-diagnosis-and-medical-management

  3. Teloken P, Katz D. Medical Management of Peyronie’s Disease: Review of the Clinical Evidence. Medical Sciences. 2019;7(9):96.

  4. Aita G, Ros CTD, Silvinato A, Bernardo WM. Peyronie’s disease: clinical treatment. Rev Assoc Med Bras. [Internet]. 2019 Oct [cited 2020 Nov 30]; 65(10): 1231-1239. Recovered from: http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0104- 42302019001001231&lng=en.

  5. Ferri FF. Peyronie Disease. In: Ferri's Clinical Advisor 2021 E-Book: 5 Books in 1. Elsevier Health Sciences; 2020. p. 1091.e2–1092.e5.

  6. Brant WO, Bella AJ, Lue TF. [Internet]. Richie JP, Chen W, editors. Surgical management of Peyronie's disease. Wolters Kluwer; 2019 [cited 2020Jul26]. Recovered from: https://www.uptodate.com/contents/surgical-management-of-peyronies-disease/print

  7. Lara-Becerra JA. EXPERIENCIA CON LA TÉCNICA QUIRÚRGICA HORTON- DEVINE EN PACIENTES CON ENFERMEDAD DE PEYRONIE: SERIE DE CASOS[thesis]. [Ciudad de Mexico]: IMSS; 2019. p. 1–36.

  8. Seftel AD, Yang H. Diagnosis and Management of Peyronie’s Disease. In: Campbell Walsh Wein Urology. 12th ed. Elsevier Health; 2020. p. 1599–626.

  9. Babu A, Kayes O. Recent advances in managing Peyronie’s disease [version 1; peer review: 2 approved]. F1000Research 2020, 9(F1000 Faculty Rev):381. doi: https://doi.org/10.12688/f1000research.20557.1

  10. Segundo A, Glina S. Prevalence, Risk Factors, and Erectile Dysfunction Associated With Peyronie’s Disease Among Men Seeking Urological Care. Sex Med. 2020 Jun;8(2):230–6.

  11. Piamo-Morales AJ, García-Rojas MA. Uso de la elastosonografía en el diagnóstico de la enfermedad de Peyronie. Acta Médica del Centro. 2020;14(2):257–67.

  12. Gabrielsen JS. Peyronie's disease: is it genetic or not?. Transl Androl Urol.2020;9(Suppl 2):S262-S268. doi: 10.21037/tau.2019.10.21

  13. Allameh F, Razzaghi M, Rayegani SM, Fallah-Karkan M, Ranjbar A, Rahavian A, etal. Laser Therapy for Peyronie’s Disease: A Randomized Control Double-Blind PilotStudy. J Lasers Med Sci. 2019;10(5):37–42.

  14. Serefoglu EC, Smith TM, Kaufman GJ, Yafi FA, Hellstrom WJG. Factors AssociatedWith Erectile Dysfunction and the Peyronie's Disease Questionnaire in Patients WithPeyronie Disease. Urology. 2017 Sep;198(6):155–60.

  15. Farrell MR, Ziegelmann MJ, Levine LA. Minimally invasive therapies for Peyronie's disease: the current state of the art. Transl Androl Urol. 2020;9(Suppl 2):S269-S283. doi: 10.21037/tau.2019.08.06

  16. DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995 - . Record No. T113775, Peyronie Disease; [updated 2018 Nov 30, cited place cited date here]. Recovered from: https://www.dynamed.com/topics/dmp~AN~T113775.

  17. Tsambarlis P, Levine LA. Nonsurgical management of Peyronie's disease. Nat RevUrol. 2019 Mar;16(3):172–86.

  18. Teron G, Gueglio G, Silva-Garretón A, Mayer M, Layús O, Rey-Valzacchi G. Utilización de pentoxifilina en fase aguda de enfermedad de La Peyronie. Revista Argentina de Urología. 2019;84(1):23–9.

  19. Rachid M, Gallouo M, Graiouid M, Allali S, Seffar A, et al. Assessment of sexuality in patients with Peyronie’s disease. Int J Sex Reprod Health Care. 2000;3(1):001- 004. doi: 10.17352/ijsrhc.000008.




2020     |     www.medigraphic.com